Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
1 - 10 of 74
- Druglike FAPIs with maximal target residence time: chemical discovery and biological characterization.From1 Jan 2024 → TodayFunding: IOF - technology concept exploration
- Potent intra-tumoral autophagy blocking with kinase PROTACs and inhibitors.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Cell-type specific delivery of autophagy inducers as a strategy to address localized autophagy impairment in diseaseFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Directed optimization of highly selective DPP9 inhibitors for chemical biology and translational research.From1 Nov 2023 → TodayFunding: FWO fellowships
- Characterization and validation of novel autophagy inducers identified via high-throughput screening: a therapeutic option for the treatment of advanced atherosclerosis.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- AUTAC- and PROTAC-mediated degradation of DPP9 to induce pyroptosis: a novel treatment strategy in acute myeloid leukemia.From1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- Development of a pancreatic cancer drug-nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure (PaCaNano).From1 Sep 2023 → TodayFunding: FWO research project (including WEAVE projects)
- OncoProToolsFrom1 Jun 2023 → TodayFunding: BOF - projects
- DPP9 degradation-induced pyroptosis for treatment of acute myeloid leukemia (DPP9-TACDrug).From1 Apr 2023 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Diagnostic and theranostic targeting of fibroblast activation protein (FAP) with goed nanoparticles decorated with FAPIs and FAPI fragments.From1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
11 - 20 of 129
- Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients(2022)
Authors: An Bracke, Emilie De Hert, Michelle De bruyn, Karen Claesen, Gwendolyn Vliegen, Alexandra Vujkovic, Lida van Petersen, Fien De Winter, An Hotterbeekx, Isabel Brosius, et al.
Pages: 4 - 11 - Profiling and structural investigation of dihydrotriazine-based DHFR inhibitors and hydantoin-derived DprE1 inhibitors in search of novel antimycobacterials(2021)
Authors: Koen Augustyns, Pieter Van Der Veken, Robert Bates
Number of pages: 215 - Strecker-derived methodology for library synthesis of N-acylated alpha-aminonitriles(2021)
Authors: Pedro Goncalves, Anke Peeraer, Yves Adriaenssens, Lara Zonnekein, Philippe Franck, Bert Maes, Koen Augustyns, Pieter Van Der Veken
Pages: 1328 - 1338 - Prolyl carboxypeptidase mediates the c-terminal cleavage of (pyr)-apelin-13 in human umbilical vein and aortic endothelial cells(2021)
Authors: Emilie De Hert, An Bracke, Isabel Pintelon, Eline Janssens, Anne-Marie Lambeir, Pieter Van Der Veken, Ingrid De Meester
- The C-terminal cleavage of angiotensin II and III is mediated by prolyl carboxypeptidase in human umbilical vein and aortic endothelial cells(2021)
Authors: Emilie De Hert, An Bracke, Anne-Marie Lambeir, Pieter Van Der Veken, Ingrid De Meester
- ATG4B inhibitor UAMC-2526 potentiates the chemotherapeutic effect of gemcitabine in a Panc02 mouse model of pancreatic ductal adenocarcinoma(2021)
Authors: Sedigheh Takhsha, Christel Vangestel, Muhammet Tanc, Sven De Bruycker, Maya Berg, Isabel Pintelon, Sigrid Stroobants, Guido De Meyer, Pieter Van Der Veken, Wim Martinet
- In vitro evaluation of the squaramide-conjugated fibroblast activation protein inhibitor-based agents AAZTA5.SA.FAPi and DOTA.SA.FAPi(2021)
Authors: Euy Sung Moon, Yentl Van Rymenant, Sandeep Battan, Joni De Loose, An Bracke, Pieter Van Der Veken, Ingrid De Meester, Frank Rösch
- In vitro and in situ activity-based labeling of fibroblast activation protein with UAMC1110-derived probes(2021)
Authors: Yentl Van Rymenant, Muhammet Tanc, Roos Van Elzen, An Bracke, Olivier De Wever, Koen Augustyns, Anne-Marie Lambeir, Mark M. Kockx, Ingrid De Meester, Pieter Van Der Veken
- Strecker-type reactions and MSAS as tools for protease inhibitor discovery(2021)
Authors: Pedro Santos Gonçalves, Pieter Van Der Veken, Koen Augustyns
Number of pages: 219 - Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics(2021)
Authors: Euy Sung Moon, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Sarah Stephan, An Bracke, Pieter Van Der Veken, Ingrid De Meester, Frank Roesch
Pages: 476 - +
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)